clinical research prime

Non-Atypical Endometrial
Hyperplasia Treatment

  • This is a Phase 3 study evaluating the proportion of women with complete resolution of nonatypical endometrial hyperplasia when treated with Mirena or oral Medroxyprogesterone acetate for 6 months.
  • Participants will also receive study related treatment at no cost and will be compensated for time and travel.

Eligible participants must meet following criteria:

  • 18+ years old

  • Have been diagnosed with Non-Atypical Endometrial
    Hyperplasia